Call for Abstract

14th World Congress on Pharmacology and Drug Safety, will be organized around the theme “Manifesto for Pharmacology and Drug Safety Surveillance: from Principles to Practice”

Euro Pharmacology 2019 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Euro Pharmacology 2019

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Ethnopharmacology is the study of medicinally used substances, especially folk remedies, by diverse cultural or ethnic groups. Traditional medicine is a term applied to pre-scientific medical systems that possess bodies of medical knowledge, including pharmacopoeia, that are passed through generations from healer to healer. The combined use of vaccines and immunostimulants is emerging as one of the innovative approaches in adjuvant development. The role of herbal drugs as immunomodulator agents are well-documented and their importance in bioprospecting is obvious.


  • Track 1-1Herbal drug industry
  • Track 1-2Medicinal plant use
  • Track 1-3Ethnopharmacology of medicinal plants
  • Track 1-4 Traditional medicine
  • Track 1-5Extraction and isolation procedures
  • Track 1-6Phytochemicals research
  • Track 1-7Development of new drugs against severe illeness

Pharmacovigilance is the process of monitoring the safety of medicines as used in everyday practice or in clinical programs. It helps to identify previously unrecognized adverse effects, adverse events or changes in the patterns of adverse effects. It is useful for assessing the risks and benefits of medicines to determine what action, if any, is necessary to improve their safe use. It provides information to users to optimize safe and effective use of medicines thereby monitoring the impact of any action taken.



  • Track 2-1Drug monitoring
  • Track 2-2Specific patient populations & drug safety
  • Track 2-3Case reports of acute & chronic poisoning
  • Track 2-4Adverse affects of medicines with chemicals other medicines & food
  • Track 2-5Abuse and misuse of medicines
  • Track 2-6Study of drug related deaths
  • Track 2-7substandard medicines
  • Track 2-8Medication errors
  • Track 2-9Postmarketing legislation
  • Track 2-10Product survelliance
  • Track 2-11Pharmaceutical preparations - adverse reactions
  • Track 2-12Minimizing drug side effects

Careful study of adverse drug events may identify diagnostic features, syndromes or pathogenic mechanisms. Moreover, clinical, pathological and epidemiological information relating to adverse reactions is necessary for a full understanding of the nature of an adverse reaction and for identifying patients at risk. Pharmacological formulations are potentially harmful to the individuals taking the drugs. There is need to ascertain the safety of new drugs before allowing them to be marketed.


  • Track 3-1Individual case safety report
  • Track 3-2Coding of adverse events
  • Track 3-3Seriousness determination
  • Track 3-4Expedited & clinical trial reporting
  • Track 3-5Spontaneous reporting
  • Track 3-6Aggregate reporting & other reporting methods

Risk management analysis of drugs include systematic processes. These systematic processes with respect to risk designed to facilitate, coordinate, and improve science-based decision making. An effective quality risk management approach can further ensure the high quality of the drug product to the patient by providing a proactive means to identify and control potential quality issues during development and manufacturing.

  • Track 4-1Risk and crisis management
  • Track 4-2Pharmacovigilance & National Drug Regulatory Authority
  • Track 4-3Causality assessment
  • Track 4-4Signal detection
  • Track 4-5Risk management plans
  • Track 4-6Risk/benefit profile of drugs
  • Track 4-7Use of statistical softwares
  • Track 4-8Data manipulation, Statistical Methods

Ecopharmacovigilance as branch of the field of pharmacovigilance for the environment is recognized worldwide as crucial to minimize the environmental risk of pharmaceutical pollutants. Ecopharmacovigilance can be defined as the science and activities concerning detection, assessment, understanding, and prevention of adverse effects or other problems related to presence of pharmaceuticals in the environment, which effect both human and other animal species.



  • Track 5-1 Environmental data on medicinal products
  • Track 5-2Tracking data on environmental exposure
  • Track 5-3Environmental risk management plans
  • Track 5-4Risk identification, promotion of environmental monitoring
  • Track 5-5Global perspective on ecopharmacovigilance issues
  • Track 5-6After product launch risks and effects

Postmarketing surveillance of drugs is the practice of safety monitoring of the pharmaceutical drugs or medical devices after their release into the marketplace. This monitoring is an important part of the science of pharmacovigilance. The key role of post-marketing surveillance is to assure the efficacy and safety of drugs after they go into the market. Its role is also to establish proper methods of use of drugs consists of three systems, and they are the ADR collecting and reporting system, the reexamination system, and the reevaluation system.



  • Track 6-1Mandatory reporting
  • Track 6-2Voluntary reporting
  • Track 6-3Data Analysis
  • Track 6-4Communications
  • Track 6-5Postmarketing surveillance
  • Track 6-6Safe use initiative
  • Track 6-7Sentinel system
  • Track 6-8Safety first initiative

Drug safety evaluation program is of paramount importance in the development of any new drug. Drug metabolites can play a significant role in overall drug toxicity and it is now accepted as a significant issue in drug development. The drug testing process begins with laboratory investigation, during this phase, extensive chemical and animal studies are performed. This helps to acquire a better understanding of how the drug works. Following this testing phase, the drug’s safety is assessed in a small group of healthy human volunteers. If all goes quite good, and the drug is deemed safe, its efficacy will be tested on a group of patients who have the targeted condition.



  • Track 7-1Pharmacokinetics/ PBPK modeling
  • Track 7-2Disease models
  • Track 7-3Inhalation toxicology
  • Track 7-4Systems biology studies
  • Track 7-5Bioinformatics
  • Track 7-6Data integration
  • Track 7-7Biomarker development

In recent times, self-medication with OTC and herbal medicines is a growing area and the possibility of experiencing an ADR or a safety concern following incorrect use should also be recognized for this group of products. It should be easy to report a suspected reaction, also for individuals who do not obtain their medicines on prescription.



  • Track 8-1Traditional & compliementary medicine
  • Track 8-2Herbals, Vaccines, biological medicines, Blood Products, Medical Devices
  • Track 8-3Preclinical research & preclinical safety assessment testing
  • Track 8-4Data processing

Today’s increasing pace of innovation in the Life-Sciences industry is resulting in ever larger number of drugs and medical devices coming to the market every year. Simultaneously, geographical expansion into newer markets has resulted in exponential business growth. Despite the continued work during the past few decades towards harmonization of regulations across various ICH regions, the fact remains that there are wide differences in regulatory bodies and the respective regulations they mandate on life sciences companies functioning in their ambit.



  • Track 9-1Globalization & web-based sales and information
  • Track 9-2Broader safety concern
  • Track 9-3Public health versus pharmaceutical industry growth
  • Track 9-4Monitoring established products
  • Track 9-5Attitudes, perceptions to benefit & harm in pharmacovigilance
  • Track 9-6Outcomes & impact- pharmacovigilance

Neuropharmacology is the study of drugs that alter processes controlled by the nervous system. Molecular neuropharmacology involves the study of neurons and their neurochemical interactions, with the overall goal of developing drugs that have beneficial effects on neurological function. Neuropharmacology is merely concerned with neuromodulators, enzymes, second messengers, co-transporters, ion channels, neurotransmitters, neuropeptides, neurohormones, receptor proteins and their interactions in the central and peripheral nervous systems.


Psychopharmacology is the branch of pharmacology dealing with the study of the actions and the effects of psychoactive drugs. Psychopharmacology is an interdisciplinary field combining psychology with pharmacology and dealing largely with psychotropic drugs, neurohormones, and, neurotransmitters.


  • Track 10-1Neurochemical interactions
  • Track 10-2Molecular neuropharmacology
  • Track 10-3Behavioural neuropharmacology
  • Track 10-4Targets of drug action in CNS
  • Track 10-5Drugs acting on chemical signaling
  • Track 10-6Psychopharmacological substances and physchopharmacological research
  • Track 10-7Neuropsychopharmacology
  • Track 10-8Dose response relation in psychiatric medicine
  • Track 10-9Psychotherapy and innovative psychological approaches

Molecular pharmacology is a field of pharmacology. The branch of pharmacology is concerned with the study of molecular basis of pharmacology. Molecular pharmacologists study the molecular study of pharmaceuticals and natural compounds used in the treatment of disease, and they also study disease on a molecular basis with the goal of developing pharmacologically active agents which could be used in the treatment of disease.


Clinical pharmacology is a medical discipline and branch of pharmacology which, on a scientific basis, combines clinical expertise and pharmacology with the goal of improving efficacy and safety in the clinical use of drugs. The significant role of drug therapy in many fields of medicine is the background for establishing clinical pharmacology as a separate discipline.


  • Track 11-1ADME of drugs
  • Track 11-2Intercellular communication
  • Track 11-3Pharmacology of transcription
  • Track 11-4G-Protein-coupled receptors
  • Track 11-5Drug–receptor interactions
  • Track 11-6Receptors and modulation of their response
  • Track 11-7Cellular basis of pharmacokinetics
  • Track 11-8Molecular cloning of drug targets
  • Track 11-9Structure-guided drug design
  • Track 11-10Pharmacogenomics
  • Track 11-11Drug Development
  • Track 11-12Drug interactions
  • Track 11-13Adverse drug effects
  • Track 11-14Rational Prescribing
  • Track 11-15Pharmacology of defence process

Systems pharmacology can be defined as the application of systems biology principles to the field of pharmacology. It seeks to understand how drugs affect the human body as a single complex biological system. Instead of considering the effect of a drug to be the result of one specific drug-protein interaction, systems pharmacology considers the effect of a drug to be the outcome of the network of interactions a drug may have.



  • Track 12-1Cardiovascular pharmacology
  • Track 12-2Pharmacogenetics in clinical practice
  • Track 12-3Physiological interactions with biological systems
  • Track 12-4genetic interactions
  • Track 12-5Protein–protein interactions
  • Track 12-6Chemical-protein interactions
  • Track 12-7Gastropharmacology
  • Track 12-8Respiratory pharmacology
  • Track 12-9Immunopharmacology
  • Track 12-10Molecular studies and genomic analysis

Nursing Pharmacology is the study of how guidelines for nurses about the substances that interact with living organisms to produce a change in function. It deals with the research, discovery, and characterization of chemicals which show biological effects and the illumination of cellular and organism function in relation to these chemicals.

Anesthesia pharmacology is the study of pharmacological action of anesthetics, local or parenteral when injected or administered into the body.

  • Track 13-1Geriatric pharmacology
  • Track 13-2Anesthetics doses and routes of administration
  • Track 13-3Other important drugs
  • Track 13-4Antiemetics and related drugs
  • Track 13-5Central nervous system drugs
  • Track 13-6Cardiovascular drugs
  • Track 13-7Core drugs in anaesthetic practice
  • Track 13-8Pharmacology management of asthama
  • Track 13-9Pediatric pharmacology
  • Track 13-10Endocrine pharmacology
  • Track 13-11Adverse reactions, precautions and interactions of anesthetics

Biochemical Pharmacology use methods of molecular biology, biochemistry, cell biology, structural biology, and cell physiology to define the mechanisms of drug action.  It helps to know how drugs influence the organism by studies on intact animals, organs, cells, sub-cellular compartments and individual protein molecules.

  • Track 14-1Drugs acting on biochemical pathways
  • Track 14-2Drug Delivery
  • Track 14-3Ribonucleic acids as drug and drug targets
  • Track 14-4Cancer chemotherapy
  • Track 14-5Chemotherapy to infectious diesease
  • Track 14-6Intermediate metabolism
  • Track 14-7Eicosanoids and related drugs
  • Track 14-8Pharmacology of nitric oxide
  • Track 14-9harmones and enzymes as drug targets
  • Track 14-10Pharmacology of cell excitation drugs
  • Track 14-11Drug metabolism
  • Track 14-12Pharamcodynamics and pharmacokinetics of drugs
  • Track 14-13Drug Discovery

Pharmacogenetics can be referred as the study of genetically determined variations that are exposed by the effects of drugs after their administration into the body. Pharmacogenetics strictly eliminates those hereditary disorders in which the symptoms are usually precipitated or aggravated by the effect of drugs.

Pharmacogenomics is the study of the human genome, and its structure as relates to genes which are involved in drug absorption, therapeutic action and elimination. Pharmacogenomics acts as a device for drug discovery.





  • Track 15-1Predicting drug-drug interactions
  • Track 15-2Theragnostics
  • Track 15-3Pharmacogenomics applications in drug development
  • Track 15-4Drug metabolizing enzymes
  • Track 15-5Personalized medicine
  • Track 15-6Cancer-therapy-monoclonal antibodies
  • Track 15-7Biomarkers
  • Track 15-8Drug devolpment, metabolism
  • Track 15-9Pharmacogenomics in personalized therapuetics
  • Track 15-10Pharmacogenetic phenotypes
  • Track 15-11harmacogentic study designs & considerations
  • Track 15-12Genomic basis of pharmacogenetics
  • Track 15-13Exogenous& endogenous factors of drug response
  • Track 15-14Polypharmacy

Toxicology is a branch of science that deals with poisons and their effect on the living organisms. A poison can be defined as any substance that causes a harmful effect when administered, either by accident or design, to a living organism. Toxicology also includes the study of harmful effects which are the cause of various kinds of physical phenomena, such as radiation and noise.




  • Track 16-1Medical toxicology
  • Track 16-2Comprehensive Toxicology
  • Track 16-3Systems toxicology
  • Track 16-4Predictive Toxicology
  • Track 16-5Organ Toxicity
  • Track 16-6Exploratory & Discovery Toxicology
  • Track 16-7Economic Toxicology
  • Track 16-8Environmental toxicology
  • Track 16-9Analytical toxicology
  • Track 16-10Descriptive and Mechanistic toxicology
  • Track 16-11Drug and Chemical Toxicology
  • Track 16-12Pediatric and Geriatric Toxicology
  • Track 16-13Clinical toxicology
  • Track 16-14Computational toxicology
  • Track 16-15Inhalation toxicology
  • Track 16-16Systemic toxicology
  • Track 16-17Immunotoxicology
  • Track 16-18Human genetic toxicology
  • Track 16-19Nanotoxicology
  • Track 16-20Food & nutritional toxicology
  • Track 16-21Molecular & cellular toxicology
  • Track 16-22Computerized modeling

There are various tests for the determination of toxicology. These tests are carried out by pharmaceutical industries biotechnology companies and by contract research organizations. The toxicity of substances can be observed by studying the accidental exposures to a substance or by in vitro studies using cells/ cell lines or by in vivo exposure on experimental animals. Each year there are around a million of primates and non–primates used for toxicology tests in Europe. Animal testing is currently banned for cosmetic purposes across the European Union.

  • Track 17-1Genetoxicity & safety pharmacology
  • Track 17-2Forensic toxicological analysis
  • Track 17-3Workplace drug testing
  • Track 17-4Diagnostic or hospital drug testing
  • Track 17-5Drug reaction testing
  • Track 17-6Omics technologies
  • Track 17-7Microarray technology
  • Track 17-8 Experimental toxicology
  • Track 17-9Toxicological screening methods
  • Track 17-10oxicity evaluatim
  • Track 17-11Toxicity testing in preclinical development
  • Track 17-12In vitro toxicity testing
  • Track 17-13ADME tests
  • Track 17-14Animal testing

The global pharmaceutical industry is a global industry that is a highly controlled, capital intensive, and which is driven by intensive research and development expenditures. The industry is primarily privately owned and is technologically sophisticated. The global pharmaceutical market is forecasted to grow to US$ 842 billion in 2010, an equivalent CAGR of 6.9% over the next five years.



  • Track 18-1R & D Investments
  • Track 18-2Worldwide prescription drug & OTC sales
  • Track 18-3Anti-diabetics & anti- rheumatics market
  • Track 18-4Oncology market
  • Track 18-5Biosimilars & other markets
  • Track 18-6Vaccine R & D
  • Track 18-7Pharmerging vs developed markets
  • Track 18-8Drug pricing
  • Track 18-9Market Revenue forecast
  • Track 18-10Pharma economical footprint
  • Track 18-11Healthcare achievements and challenges
  • Track 18-12Biopharmaceuticals market
  • Track 18-13Generic versus branded pharmaceutical products
  • Track 18-14Top selling drugs worldwide

Pharmacoepidemiology is the study of drug efficacy, toxicity and patterns of use in large populations. The importance of pharmacoepidemiology occurs when the pharmacological effects, adverse effects and interactions of the medications are ignored. Pharmacoepidemiology involves the programmatic efforts of conduct and evaluation to improve medication use on a populace basis.


  • Track 19-1Study designs
  • Track 19-2Molecular pharmacoepidemiology
  • Track 19-3Patient safety
  • Track 19-4Novek approaches to pharmacoepidemiology study design, statistical analyisis
  • Track 19-5Confounding
  • Track 19-6Methodological issues in pharmacoepidemiology studies of vaccine safety and devices
  • Track 19-7Validity of pharmacoepidemology drug, diagnosis data
  • Track 19-8Pharmacoeconomics
  • Track 19-9Randomized controlled trials
  • Track 19-10Premarkting &drug utilization review
  • Track 19-11Bioethical issues in research
  • Track 19-12Prescription-event monitoring
  • Track 19-13Cohort studies & Bias Studies
  • Track 19-14Case-cross over study
  • Track 19-15Cross-sectional studies
  • Track 19-16Case-control surveillance
  • Track 19-17Studies of benefit or safety of pharmaceuticals, biologics, medical devices

Pharmaceutical chemists are involved in the development and assessment of therapeutic compounds. Pharmaceutical chemistry encompasses drug design, drug synthesis, and the evaluation of drug efficacy (how effective it is in treating a condition) and drug safety. Drug discovery is the core of pharmaceutical chemistry. The drug discovery process includes all the stages of drug development, from targeting a disease or medical condition to toxicity studies in animals, or even, by some definitions, testing the drug on human subjects. Typically, conditions that affect a larger percentage of the population receive more attention and more research funding.



  • Track 20-1Drug design stratagies
  • Track 20-2 Lead Optimization
  • Track 20-3CADD, SBDD, LBDD, in silico drug design
  • Track 20-4Rational drug development
  • Track 20-5Chromatographic methods for analysis
  • Track 20-6Physiochemical properties of drugs
  • Track 20-7Steriochemistry
  • Track 20-8Stability of drugs and medicines
  • Track 20-9All classes of drugs SAR, action
  • Track 20-10Volumetric analysis of drugs
  • Track 20-11Chemisty of acids and bases
  • Track 20-12Drug metabolism
  • Track 20-13Biotechnology & drug discovery
  • Track 20-14Clinical Evaluation

Safety Pharmacology helps to evaluate adverse pharmacodynamic pathophysiological effects of a substance observed in toxicology or clinical studies. Toxic drug effects on organ functions are not readily detected by standard toxicological testing. Safety pharmacology helps to investigate the mechanism of the adverse pharmacodynamic effects observed and or suspended.

  • Track 21-1Selection, design of safety pharmacological studies
  • Track 21-2Integrating safety pharmacology end points
  • Track 21-3Integrated core battery assessment
  • Track 21-4Alternate Models
  • Track 21-5Frontloading
  • Track 21-6Screening assays
  • Track 21-7General safety assays
  • Track 21-8Core Battery Organ Systems & studies
  • Track 21-9Pre-Clinical safety pharmacology & evaluation
  • Track 21-10Transistional safety pharmacology

Environmental pharmacology which can be defined as the effect of pharmaceuticals and house care products on the environment and the ecosystem. Environmental pharmacology is a relatively new and emerging specialty of pharmacology. It involves the study of gene-environment interaction, drug-environment interaction and toxin-environment interaction.


  • Track 22-1Source & fate of pharmaceutical products
  • Track 22-2Environmental risk assessment
  • Track 22-3Environmental ethics and guidelines- safe disposal
  • Track 22-4Pharmaceutical disposal-environment standards
  • Track 22-5Gene environment interaction
  • Track 22-6Miscellaneous toxicity
  • Track 22-7Toxin-environment interaction
  • Track 22-8Effect of xenobiotics on environment & ecosystem
  • Track 22-9Source & fate of household products
  • Track 22-10Environmental classification of drugs